ArticleFrontiers in immunology2026
Peripheral immune profiles separate disease activity stages in birdshot uveitis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Birdshot uveitis (BU) is a chronic, debilitating posterior uveitis strongly associated with HLA-A*29, supporting a suspected autoimmune etiology. We used high-dimensional mass cytometry and clinical stratification to characterize the peripheral immune landscape in BU and identify disease activity-dependent signatures. Methods: In this cross-sectional study, we included 36 treated BU patients and 31 age- and sex-matched healthy controls (HCs). All participants underwent comprehensive ophthalmologic evaluation with multimodal imaging. Patients were stratified by an expert ophthalmologist into Inactive, Active, and Burned-out disease activity groups based on clinical and imaging findings. Peripheral blood and serum were collected for immunoprofiling using a 37-marker mass cytometry panel and multiplex cytokine analysis. Results: Compared with HCs, BU patients showed increased frequencies of Th17 cells, CD146 Discussion: Integrated peripheral immune profiling with clinical stratification revealed distinct disease activity-dependent and treatment-associated signatures in BU. Inactive and Burned-out patients showed predominantly exhausted or anergic T cell phenotypes, whereas active disease featured heightened T cell activation and mature NK cell expansion. These findings demonstrate both the value and challenges of interpreting immune profiles in treated patients, especially with biologics such as tocilizumab that alter receptor detectability. Despite the heterogeneity typical of rare-disease cohorts, activity-associated immune patterns were detectable. Future studies should evaluate the diagnostic, prognostic, and monitoring utility of these signatures in BU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.